marked.bio

anti-PD-1 antibody · antibody

spartalizumab

2 active trials across 6 of our biomarkers, targeting PD-1. Not approved for any biomarker on marked.bio yet.

Also known as PDR001.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 7 Phase 2
MSI-H / dMMR 1 1 Phase 1/2
ALK fusion 0 1 –
EGFR exon 19 deletion / L858R 0 1 –
KRAS G12C 0 2 –
KRAS G12D 0 2 –

Trials

2 of 11 trials shown

  1. Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

    Active, not recruiting Phase 1/2 University Hospital, Bordeaux Started 2022Primary completion 2025-08 NCT05210413

    spartalizumabLow-dose Pazopanib in Pediatric CohortLow-dose Pazopanib in Adult Cohort

    …her) and/or tumor with High mutation rate (\>10 somatic mutations/Mb) and/or suffering of Mismatch repair-deficient syndrome.

    MSI-H / dMMRRefractory or Recurrent Solid Tumor

  2. PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

    Active, not recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020Primary completion 2027-09 NCT04544111

    trametinib FDA EUdabrafenib FDA EUspartalizumab

    … the patient's thyroid tumors (primary tumor, recurrent tumor, or metastases) possesses a BRAFV600- mutation (e.g.

    BRAF V600EThyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer